270 related articles for article (PubMed ID: 29533020)
1. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients.
Yang B; Xie L; Zhang H; Zhu Q; Du Y; Luo X; Chen X
J Gynecol Oncol; 2018 May; 29(3):e35. PubMed ID: 29533020
[TBL] [Abstract][Full Text] [Related]
2. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
[TBL] [Abstract][Full Text] [Related]
3. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
Xi Y; Liu G; Liu D; Jiang J; Gong R
Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
[TBL] [Abstract][Full Text] [Related]
5. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
6. [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer].
Dong YT; Guan J; Yang BY; Yierfulati G; Xue Y; Chen XJ
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):729-735. PubMed ID: 38462352
[No Abstract] [Full Text] [Related]
7. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
8. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia.
Wang Y; Zhou R; Wang H; Liu H; Wang J
Int J Gynecol Cancer; 2019 May; 29(4):699-704. PubMed ID: 30826750
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
[TBL] [Abstract][Full Text] [Related]
10. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
11. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
12. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
Shikeli S; Gowri V; Rawahi TA
JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
14. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome.
Wang L; Luo X; Wang Q; Lv Q; Wu P; Liu W; Chen X
J Gynecol Oncol; 2021 Sep; 32(5):e70. PubMed ID: 34132069
[TBL] [Abstract][Full Text] [Related]
15. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
16. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
17. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
18. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
19. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
20. Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study.
Wang Y; Zhou R; Zhang X; Liu H; Shen D; Wang J
BMC Womens Health; 2021 Jun; 21(1):252. PubMed ID: 34162378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
